| 何苗,王翎.生物靶向制剂与高 T2型哮喘[J].安徽医药,2024,28(2):406-410. |
| 生物靶向制剂与高 T2型哮喘 |
| Targeted biological agents for T2-high asthma |
| |
| DOI：10.3969/j.issn.1009-6469.2024.02.044 |
| 中文关键词: 哮喘 白细胞介素 -4 白细胞介素 -5 白细胞介素 -13 生物制剂 高 T2哮喘 生物标志物 靶向治疗 |
| 英文关键词: Asthma Interleukin-4 Interleukin-5 Interleukin-13 Biological agent T2-high asthma Biomarkers Targeted therapy |
| 基金项目:苏州市医学重点扶持学科( SZFCXK20211) |
|
| 摘要点击次数: 325 |
| 全文下载次数: 191 |
| 中文摘要: |
| 哮喘是一种异质性疾病，约 50%的哮喘病人存在 2型炎症， T2哮喘主要由包括白细胞介素( IL)-4、IL-5和 IL-13等 T2细胞因子驱动的气道炎症引起，全球哮喘倡议( GINA)指南建议对 T2炎症引起的严重哮喘病人使用生物制剂，当前和未来的生物疗法正在显著改变全球严重哮喘管理。这些新的治疗方案使得实施表型 /内型特异性治疗成为可能。该文回顾了目前用于高 T2型哮喘生物制剂的作用机制、功效和适应证，讨论了在这些生物制剂之间进行选择时的考虑因素。 |
| 英文摘要: |
| Asthma is a heterogeneous disease. About 50% of patients with asthma have type 2 inflammation. T2 asthma is mainlycaused by airway inflammation driven by T2 cytokines, including interleukins IL-4, IL-5, IL-13,etc. The Global Initiative for Asthma(GINA) recommends the use of biological agents in patients with severe asthma caused by T2 inflammation. Current and future biologictherapies are remarkably changing the management of severe asthma globally. These new therapies make it possible to implement spe.cific phenotypes/endophenotypes treatments for asthma patients. This article reviews the mechanism, efficacy and indications of current biological agentsapplied to T2-high asthma, and discusses the factors considered when choosing among them. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
